Screening the endophytic flora of<i>Wollemia nobilis</i>for alternative paclitaxel sources

Staniek, Agata; Woerdenbag, Herman J.; Kayser, Oliver

doi:10.1080/17429141003714721

Cited by 10 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…133 The one piece missing in the biosynthetic process, the presence of the gene for taxadiene synthetase was identified but the production of the metabolite was not fully confirmed in the view of some. 134,135 The possibilities relating to the production of this agent via fungi have been discussed recently by Flores-Bustamente et al 136 and recently further evidence of production from a Taxus globosa source was reported. 137 …”

Section: Discussionmentioning

confidence: 97%

Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010

2012

View full text Add to dashboard Cite

This review is an updated and expanded version of the three prior reviews that were published in this journal in 1997, 2003 and 2007. In the case of all approved therapeutic agents, the time frame has been extended to cover the 30 years from January 1st 1981 to December 31st 2010 for all diseases world-wide, and from 1950 (earliest so far identified) to December 2010 for all approved antitumor drugs world-wide. We have continued to utilize our secondary subdivision of a “natural product mimic” or “NM” to join the original primary divisions, and have added a new designation “natural product botanical” or “NB” to cover those botanical “defined mixtures” that have now been recognized as drug entities by the FDA and similar organizations. From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well. Thus, in the area of cancer, over the time frame from around the 1940s to date, of the 175 small molecules, 131 or 74.8% are other than “S” (synthetic), with 85 or 48.6% actually being either natural products or directly derived there from. In other areas, the influence of natural product structures is quite marked with, as expected from prior information, the anti-infective area being dependent on natural products and their structures. Although combinatorial chemistry techniques have succeeded as methods of optimizing structures, and have been used very successfully in the optimization of many recently approved agents, we are only able to identify only one de novo combinatorial compound approved as a drug in this 30-year time frame. We wish to draw the attention of readers to the rapidly evolving recognition that a significant number of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the “host from whence it was isolated”, and therefore we consider that this area of natural product research should be expanded significantly.

show abstract

Section: Discussionmentioning

confidence: 97%

Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010

2012

View full text Add to dashboard Cite

show abstract

“…Genes encoding for other pathway enzymes have also been sought occasionally. 91,105 The fungi indicating the presence of the ts gene included Taxomyces andreanae, 149 Fusarium redolens, 89 Gibberella intermedia, 84 Mucor rouxianus, 101 Phomopsis sp., 127 Cladosporum langeronii, 75 Phoma betae, 121 81 and several unidentified strains. 151,152 Fungi shown to have the dbat gene include Fusarium solani, 91 Cladiosporium cladosporioides, 72 Aspergillus candidus, 49 Pestalotiopsis sp., 120 Fusarium redolens, 89,90 Penicillium aurantogrisseum, 110 Botryosphaeria rhodian, 62 Cladosporium oxysporum, 44 Alternaria solani, 44 Lasiodiplodia theobromae, 99 and Aspergillus f umigatus.…”

Section: ■ Introductionmentioning

confidence: 99%

Biologically Significant and Recently Isolated Alkaloids from Endophytic Fungi

Daley¹,

Cordell

2021

J. Nat. Prod.

View full text Add to dashboard Cite

show abstract

“…Evidence as taxane producers has been also reported for strains of Cladosporium langeronii and Phomopsis sp. from Wollemia nobilis [281].…”

Section: Speciosus T Chinensismentioning

confidence: 99%

Plant Bioactive Metabolites and Drugs Produced by Endophytic Fungi of Spermatophyta

2015

View full text Add to dashboard Cite

Abstract:It is known that plant-based ethnomedicine represented the foundation of modern pharmacology and that many pharmaceuticals are derived from compounds occurring in plant extracts. This track still stimulates a worldwide investigational activity aimed at identifying novel bioactive products of plant origin. However, the discovery that endophytic fungi are able to produce many plant-derived drugs has disclosed new horizons for their availability and production on a large scale by the pharmaceutical industry. In fact, following the path traced by the blockbuster drug taxol, an increasing number of valuable compounds originally characterized as secondary metabolites of plant species belonging to the Spermatophyta have been reported as fermentation products of endophytic fungal strains. Aspects concerning sources and bioactive properties of these compounds are reviewed in this paper.

show abstract

Screening the endophytic flora ofWollemia nobilisfor alternative paclitaxel sources

Cited by 10 publications

References 34 publications

Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010

Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010

Biologically Significant and Recently Isolated Alkaloids from Endophytic Fungi

Plant Bioactive Metabolites and Drugs Produced by Endophytic Fungi of Spermatophyta

Contact Info

Product

Resources

About